Novartis AG (SWX:NOVN)
102.54
+2.42 (2.42%)
Oct 1, 2025, 9:45 AM CET
Novartis AG Revenue
Novartis AG had revenue of $14.84B USD in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.42
Revenue / Employee
$727.25K
Employees
75,883
Market Cap
193.82B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Lonza Group AG | 7.09B |
Galderma Group AG | 3.73B |
Alcon | 7.97B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Galenica AG | 4.03B |
Novartis AG News
- 9 hours ago - Novartis (NVS) Gains FDA Approval for Innovative CSU Treatment - GuruFocus
- 10 hours ago - Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - PRNewsWire
- 10 hours ago - Novartis wins FDA approval of BTK inhibitor remibrutinib for urticaria - Seeking Alpha
- 11 hours ago - US FDA approves Novartis' drug for skin disease - Reuters
- 11 hours ago - Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - GlobeNewsWire
- 1 day ago - Pharma's Direct-To-Patient Wave Hits Novartis Next - Benzinga
- 1 day ago - Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S. - WSJ
- 1 day ago - Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US - GlobeNewsWire